{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T06:41:05Z","timestamp":1786430465846,"version":"build-2736575974"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,8,1]]},"DOI":"10.1097\/qai.0b013e31817bbe93","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T15:14:03Z","timestamp":1236266043000},"page":"428-436","source":"Crossref","is-referenced-by-count":59,"title":["The A62V and S68G Mutations in HIV-1 Reverse Transcriptase Partially Restore the Replication Defect Associated With the K65R Mutation"],"prefix":"10.1097","volume":"48","author":[{"given":"Evguenia S","family":"Svarovskaia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy Y","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas A","family":"Margot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Myrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten L","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilima","family":"Kutty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katyna","family":"Borroto-Esoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210131","first-page":"87","article-title":"Resistance to protease inhibitors.","volume":"7","author":"Kuritzkes","year":"2002","journal-title":"J HIV Ther"},{"key":"R2-6-20210131","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R3-6-20210131","doi-asserted-by":"crossref","first-page":"9339","DOI":"10.1128\/JVI.74.20.9339-9346.2000","article-title":"Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1.","volume":"74","author":"Garcia-Lerma","year":"2000","journal-title":"J Virol"},{"key":"R4-6-20210131","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1086\/315317","article-title":"Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.","volume":"181","author":"Harrigan","year":"2000","journal-title":"J Infect Dis"},{"key":"R5-6-20210131","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00002030-200206140-00004","article-title":"Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.","volume":"16","author":"Margot","year":"2002","journal-title":"AIDS"},{"key":"R6-6-20210131","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/135965350300800212","article-title":"K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.","volume":"8","author":"Roge","year":"2003","journal-title":"Antivir Ther"},{"key":"R7-6-20210131","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1128\/AAC.41.4.757","article-title":"Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.","volume":"41","author":"Winters","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-6-20210131","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1468-1293.2006.00404.x","article-title":"Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.","volume":"7","author":"Margot","year":"2006","journal-title":"HIV Med"},{"key":"R9-6-20210131","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1086\/510745","article-title":"Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.","volume":"44","author":"Sungkanuparph","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R10-6-20210131","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1128\/JVI.77.10.5685-5693.2003","article-title":"A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.","volume":"77","author":"Garcia-Lerma","year":"2003","journal-title":"J Virol"},{"key":"R11-6-20210131","doi-asserted-by":"crossref","first-page":"25489","DOI":"10.1074\/jbc.M313534200","article-title":"A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions.","volume":"279","author":"Deval","year":"2004","journal-title":"J Biol Chem"},{"key":"R12-6-20210131","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1128\/JCM.43.3.1395-1400.2005","article-title":"Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.","volume":"43","author":"Weber","year":"2005","journal-title":"J Clin Microbiol"},{"key":"R13-6-20210131","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/AAC.46.11.3437-3446.2002","article-title":"Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.","volume":"46","author":"White","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-6-20210131","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1128\/AAC.00816-06","article-title":"In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.","volume":"50","author":"Margot","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-6-20210131","first-page":"125","article-title":"Update of the drug resistance mutations in HIV-1: Fall 2006.","volume":"14","author":"Johnson","year":"2006","journal-title":"Top HIV Med"},{"key":"R18-6-20210131","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jmb.2006.09.073","article-title":"Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine.","volume":"365","author":"Cases-Gonzalez","year":"2007","journal-title":"J Mol Biol"},{"key":"R20-6-20210131","doi-asserted-by":"crossref","first-page":"9440","DOI":"10.1021\/bi990709m","article-title":"Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase.","volume":"38","author":"Feng","year":"1999","journal-title":"Biochemistry"},{"key":"R21-6-20210131","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1097\/01.aids.0000189851.21441.f1","article-title":"A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT.","volume":"19","author":"White","year":"2005","journal-title":"AIDS"},{"key":"R22-6-20210131","doi-asserted-by":"crossref","first-page":"25988","DOI":"10.1016\/S0021-9258(18)35706-5","article-title":"Mechanism and fidelity of HIV reverse transcriptase.","volume":"267","author":"Kati","year":"1992","journal-title":"J Biol Chem"},{"key":"R23-6-20210131","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1128\/AAC.39.8.1888","article-title":"K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine.","volume":"39","author":"Gu","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-6-20210131","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/jnci\/81.8.577","article-title":"New soluble-formazan Assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity.","volume":"81","author":"Weislow","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"R25-6-20210131","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1128\/AAC.40.10.2404","article-title":"Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay.","volume":"40","author":"Boucher","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-6-20210131","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1128\/AAC.48.3.992-1003.2004","article-title":"Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.","volume":"48","author":"White","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-6-20210131","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1128\/AAC.41.12.2781","article-title":"A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors.","volume":"41","author":"Shi","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-6-20210131","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1128\/JVI.66.4.2232-2239.1992","article-title":"Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.","volume":"66","author":"Kimpton","year":"1992","journal-title":"J Virol"},{"key":"R29-6-20210131","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1128\/AAC.49.8.3334-3340.2005","article-title":"Quantifying mixed populations of drug-resistant human immunodeficiency virus type 1.","volume":"49","author":"Moser","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-6-20210131","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1128\/JCM.01512-06","article-title":"MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples.","volume":"44","author":"Svarovskaia","year":"2006","journal-title":"J Clin Microbiol"},{"key":"R31-6-20210131","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1128\/JVI.80.5.2380-2389.2006","article-title":"Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay.","volume":"80","author":"Wu","year":"2006","journal-title":"J Virol"},{"key":"R32-6-20210131","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1097-2765(00)80185-9","article-title":"A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase.","volume":"4","author":"Meyer","year":"1999","journal-title":"Mol Cell"},{"key":"R33-6-20210131","doi-asserted-by":"crossref","first-page":"8925","DOI":"10.1073\/pnas.90.19.8925","article-title":"Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication.","volume":"90","author":"Gao","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R34-6-20210131","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1074\/jbc.M308806200","article-title":"Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations.","volume":"279","author":"Deval","year":"2004","journal-title":"J Biol Chem"},{"key":"R35-6-20210131","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1128\/AAC.00683-06","article-title":"Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.","volume":"51","author":"Sluis-Cremer","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R36-6-20210131","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/15257770500379157","article-title":"Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.","volume":"25","author":"Feng","year":"2006","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"R37-6-20210131","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1021\/bi0121858","article-title":"Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate.","volume":"41","author":"Ray","year":"2002","journal-title":"Biochemistry"},{"key":"R38-6-20210131","doi-asserted-by":"crossref","first-page":"13965","DOI":"10.1074\/jbc.M009837200","article-title":"The valine-to-threonine 75 substitution in human immunodeficiency virus type 1 reverse transcriptase and its relation with stavudine resistance.","volume":"276","author":"Selmi","year":"2001","journal-title":"J Biol Chem"},{"key":"R39-6-20210131","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/135965350601100209","article-title":"The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations.","volume":"11","author":"White","year":"2006","journal-title":"Antivir Ther"},{"key":"R40-6-20210131","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2005.03.001","article-title":"Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1,3-dioxolan guanine.","volume":"66","author":"Feng","year":"2005","journal-title":"Antiviral Res"},{"key":"R41-6-20210131","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1126\/science.282.5394.1669","article-title":"Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.","volume":"282","author":"Huang","year":"1998","journal-title":"Science"},{"key":"R42-6-20210131","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1021\/bi00234a002","article-title":"Kinetic mechanism of DNA polymerase I (Klenow fragment): identification of a second conformational change and evaluation of the internal equilibrium constant.","volume":"30","author":"Dahlberg","year":"1991","journal-title":"Biochemistry"},{"key":"R43-6-20210131","doi-asserted-by":"crossref","first-page":"24607","DOI":"10.1016\/S0021-9258(19)74509-8","article-title":"Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase.","volume":"268","author":"Hsieh","year":"1993","journal-title":"J Biol Chem"},{"key":"R44-6-20210131","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.biocel.2004.02.028","article-title":"Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs).","volume":"36","author":"Goldschmidt","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"R45-6-20210131","first-page":"335","article-title":"Mechanisms of HIV-1 nucleoside reverse transcriptase inhibitor resistance: is it all figured out?","volume":"2","author":"Naeger","year":"2001","journal-title":"Curr Opin Investig Drugs"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00126334-200808010-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:48:24Z","timestamp":1786038504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-200808010-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,1]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31817bbe93","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8,1]]}}}